Cascades Capital Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.04M Sell
2,539
-113
-4% -$115K 1.13% 17
2026
Q1
$2.44M Sell
2,652
-147
-5% -$149K 1.02% 19
2025
Q4
$3.01M Sell
2,799
-105
-4% -$100K 1.26% 15
2025
Q3
$2.22M Buy
2,904
+59
+2% +$43.9K 0.98% 21
2025
Q2
$2.22M Buy
2,845
+309
+12% +$240K 1.14% 20
2025
Q1
$2.09M Sell
2,536
-82
-3% -$68.2K 1.13% 21
2024
Q4
$2.02M Sell
2,618
-43
-2% -$35.6K 1.08% 21
2024
Q3
$2.36M Buy
+2,661
New +$2.39M 1.3% 15

Other funds holding LLY

Cascades Capital Asset Management's LLY Position: Q2 2026 in Review

Cascades Capital Asset Management reduced its Eli Lilly (LLY) stake by 4.3% in Q2 2026, selling an estimated $115K and leaving 2,539 shares worth $3.04M. The position accounts for 1.13% of the portfolio, ranked #17.

Cascades Capital Asset Management first reported a position in LLY in Q3 2024 and has held it in 8 quarters since. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cascades Capital Asset Management held 2,539 shares of Eli Lilly worth $3.04M as of Q2 2026.
  • Cascades Capital Asset Management sold 113 Eli Lilly shares in Q2 2026, an estimated $115K.
  • Eli Lilly made up 1.13% of Cascades Capital Asset Management's portfolio in Q2 2026, its #17 holding.
  • Cascades Capital Asset Management first reported a position in Eli Lilly in Q3 2024 and has held it in 8 quarters since.
  • 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cascades Capital Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.